Sarepta's 2026 Q2 Earnings Call: Cohort 8 Data Delays and siRNA Regulatory Path Uncertainty Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $401M, down 34% YOY
• Gross Margin: 75% on net product revenues for the quarter; 78% for the first half of the year
• Operating Margin: Non-GAAP operating income of $86M for the quarter; $484M for the first half of the year

Guidance:

• 2026 total net product revenue guidance narrowed to $1.2B to $1.3B, with midpoint as appropriate reference.
• 2026 total collaboration and other revenue guidance raised to $550M to $600M, an increase of $75M from prior midpoint.
• Non-GAAP operating expense guidance tightened to $800M to $850M, low end of previous range.
• Expect total net product revenue in second half of 2026 to be modestly lower than first half.
• Elevitus revenue in Q3 expected to trend lower than Q2.
• Expect to fully enroll Cohort 8 of ENDEAVOR study by end of 2026, with 12-week data in Q1 2027.
• FDA PDUFA target action date for Amondus 45 and Vyondus 53 supplemental NDA is February 28, 2027.

Business Commentary:

Financial Performance and Cash Growth:

• Sarepta Therapeutics reported total revenues of $401 million for Q2 2026, with a 34% year-over-year decrease primarily due to lower net product revenues.
• The company ended the quarter with $945 million in cash and investments, an increase of $197 million from the prior quarter, reflecting strong operational performance and cash generation from its base business.

Commercial Performance and Elevitus Adoption:

• Sarepta's total net product revenue was $329 million, with $98 million from Elevitus and $231 million from the PMO franchise.
• Elevitus sales were steady, with improving enrollment forms indicating increasing demand and momentum, supported by enhanced commercial initiatives and improved understanding of its benefit-risk profile.

Pipeline Progress and siRNA Platform:

• Significant progress was noted in Sarepta's siRNA platform, with plans for important data readouts in the second half of the year from FSHD and DM1 programs.
• The company's biology-first approach and efficient delivery mechanisms are seen as key differentiators, with the potential for best-in-class therapies in multiple neuromuscular and rare disease indications.

Operational Profitability and Expense Management:

• Sarepta achieved GAAP operating income of $13 million and non-GAAP operating income of $86 million for Q2 2026, reflecting disciplined cost management.
• Combined R&D and SG&A expenses were managed prudently, with non-GAAP expenses decreasing 44% year-over-year, driven by restructuring and prioritization of promising programs.

Regulatory and Developmental Milestones:

• The FDA accepted supplemental new drug applications for Amondus 45 and Vyondus 53, with PDUFA target action dates set for February 28, 2027.
• Upcoming regulatory decisions and data readouts, including cohort eight data for Elevitus, are expected to clarify Sarepta's growth trajectory and inform future development plans.

Sentiment Analysis:

Overall Tone: Positive

• CEO Michael Severino stated 'our future is bright' and highlighted 'tremendous potential untapped value.' Management reported another quarter of operating profitability, increased cash by $197M, and expressed confidence in long-term opportunities. They noted 'encouraging' trends in enrollment forms and are 'very much looking forward' to upcoming data and regulatory milestones.

Q&A:

• Question from Anupam (Firm not specified): When you look at the pipeline, What really excites you about what you have going on in the pipeline? Is it something particular about the Arrowhead products or something like what Cohort 8 could do for the Elevitus franchise?
  Response: Excited about Cohort 8 data's potential to improve Elevitus benefit-risk, and about siRNA programs' strong preclinical/clinical data showing high muscle concentration and robust knockdown, with confidence in their future value.

• Question from Analyst (Firm not specified): How are you thinking about the potential separation of the two businesses, the DMD pipeline and the DM1 FSHD programs?
  Response: Sees strong synergy; DMD portfolio is a durable asset and revenue source that funds the siRNA pipeline; both areas are complementary and will be clarified by upcoming data.

• Question from Analyst (Firm not specified): On the expense side, it looks like you've lowered your OPEX guidance for this year... how will resonance of the Elevitus commercial efforts as well as the competitive dynamics for the Exxon skippers potentially influence how you think about long-term OPEX?
  Response: Comfortable with $800-900M OpEx range; will continue prudent capital allocation focused on highest probability of success and long-term value, advancing pipeline while managing commercial dynamics.

• Question from Analyst (Firm not specified): So I have a question about the regulatory strategy for the SRNA programs... can you maybe talk about your latest thinking and whether you plan to pursue accelerated approval or full approval for both indications?
  Response: Regulatory pathway for FSHD and DM1 can be either accelerated or traditional approval, data-driven; primary endpoints for phase three will be informed by MAD study readouts, with discussions to be had with regulators.

• Question from Analyst (Firm not specified): Just a clarification on some of your Elevitus commentary. You mentioned you saw a quarter-over-quarter increase in Elevitus enrollment forms. Just to clarify, are you also seeing an increase in start forms in 3Q versus 2Q?
  Response: Encouraged by improving start forms and enrollment trends; initiatives are taking hold, but revenue will translate meaningfully in 2027 given typical ~6 month lag from form to infusion.

• Question from Caroline (CIGAL): With DM1 and FSHD data approaching, can you tell us what disease characteristics make a target particularly well-suited for the Alpha V Beta 6 delivery platform, and what additional muscle diseases could become attractive expansion opportunities?
  Response: Alpha-V beta-6 is suitable for muscle diseases needing high, widespread concentration; siRNA targets toxic gain-of-function mRNA/proteins. Potential expansion to other muscle diseases with similar pathology.

• Question from Analyst (Firm not specified): I've got two questions. One is related to just the time lag to revenues for Elevitus... Does this imply that there is a longer time to fill... than the previously indicated five to six months? And then with your cohort eight in q1 of next year will you have expression data as part of that top-line release?
  Response: Time lag remains ~6 months; Cohort 8 top-line will focus on ALI (liver safety) primary goal, biopsy data timing not specified.

• Question from Morgan Stanley: Maybe just with respect to the RNA data updates expected later in the second half, you know, should we expect those more towards year end? And will you share those updates together, or do you plan to separate them out?
  Response: Updates expected in second half, timing not specified; likely released separately when data become available, as programs are considered separately.

• Question from Matt Ong (Salveen): Could you provide any more color on the metrics beyond start forms that you are seeing that support deeper elevatous penetration in the ambulatory patients? And how are you thinking of the longer-term trajectory now?
  Response: Seeing stabilization and improvement in enrollment forms, returning site engagement, new site interest, and directional alignment between HCP engagement and form submissions, signaling initiatives are taking hold.

• Question from Analyst (Firm not specified): On Amandus and Beyondus, SMBA, has the FDA indicated if there are any plans to hold an advisory committee meeting?
  Response: FDA has not indicated intent to schedule an advisory committee for Amondus and Vyondus reviews at this time.

• Question from Analyst (Firm not specified): Second question on FSHDs, there's a direct transcriptional target of Dux4 that apparently correlates to clinical disease severity. I wonder if you're looking at that in the current trial.
  Response: Evaluating Dux4-related gene panel and circulating biomarkers to validate assays and assess correlation with disease severity.

• Question from Analyst (Firm not specified): And then the last one on cohort 8 data, is there potential to revive the LGMD gene therapy programs after those cohort 8 data?
  Response: Yes, Cohort 8 data will inform pathway to submit BLA for LGMD gene therapy, which is currently on clinical hold.

• Question from David Holmes (Deutsche Bank): So I want to ask about the PMO franchise and your perception of the durability there. And in particular, how should we think about modeling the franchise next year, especially with Exondus, where we have a potential market entry of a competing Exxon 51 Skipper?
  Response: High confidence in PMO franchise durability due to long track record, real-world evidence, safety profile, and mature infrastructure; competition impact likely visible later in 2027, not imminent.

• Question from Jade (Mitchell): Regarding the MAD data in DM1 with the functional endpoint, I think, Louise, you mentioned that the goal is not or the primary goal is not to establish functional efficacy data set, can you please clarify the reason behind it?
  Response: For FSHD, primary goal is not functional efficacy due to slow disease progression; data at six months too early to show therapeutic effects; proof of biology data expected early next year.

• Question from Analyst (Firm not specified): Regarding the competitive landscape, if, let's say, one of the programs that's ahead of you in development... is able to get an accelerated path, do you think that would lessen the chances that Sarepsa could have, even with compelling data, to get an accelerated path as well?
  Response: Will evaluate regulatory landscape and data; study designed for either accelerated or traditional approval; decisions will be data-driven and based on discussions with agency.

• Question from Analyst (Firm not specified): what quantitative benchmarks does each program need to clear to justify pivotal advancement rather than continued exploration?
  Response: Need to achieve safe dose escalation, strong muscle concentration, significant target knockdown, and positive biomarker changes, benchmarking back to preclinical data.

Contradiction Point 1

Cohort 8 Data Availability Timeline

Contradiction on when the 12-week Cohort 8 data will be available.

Yun Zeng (Wedbush) - Yun Zeng (Wedbush)

2026Q2: Cohort 8 enrollment is progressing well. The 12-week data from all 25 patients is now expected in Q1 2027. - [Louise Rodino-Claypack](President of R&D)

Was there a delay, and what magnitude of impact should we expect? - Mike Old (Morgan Stanley)

2026Q2: Data from the FSHD and DM1 MAD studies are both expected in the second half of 2026. - [Michael Severino](CEO) & [Dr. Louise Rodino-Klapac](President of R&D)

Contradiction Point 2

Regulatory Path for siRNA Programs

Contradiction on the regulatory pathway being flexible versus having a specific focus.

Andrew Tsai (Jefferies) - Andrew Tsai (Jefferies)

2026Q2: The regulatory pathway for FSHD and DM1 is flexible, allowing for either accelerated or traditional approval... - [Louise Rodino-Claypack](President of R&D)

What is your envisioned primary endpoint for the siRNA programs under your regulatory strategy? - Tazeen Ahmad (Bank of America)

2026Q2: The study design is flexible for either accelerated or traditional approval. - [Dr. Louise Rodino-Klapac](President of R&D) & [Michael Severino](CEO)

Contradiction Point 3

FSHD MAD Study Data Content & Expectations

Contradiction on whether the MAD study will definitively demonstrate functional benefit.

An unnamed investor - An unnamed investor

2026Q2: For FSHD, the primary goal of the MAD study is not to definitively demonstrate functional benefit because FSHD is a slowly progressive disease, and six months of follow-up is insufficient to show stabilization or improvement. - [Louise Rodino-Claypack](President of R&D)

Can you clarify the reason for not establishing a functional efficacy dataset for the MAD data in DM1 with the functional endpoint? - Ritu Baral (TD Cowen)

2026Q1: The data will help select primary endpoints for phase III. The first proof of biology data, including safety and early signs of efficacy (like CSF knockdown), is expected early next year. - [Louise Rodino-Klapac](President of R&D)

Contradiction Point 4

Regulatory Path for Non-Ambulatory DMD

Contradiction on the immediate regulatory next steps following the Cohort 8 data.

An unnamed investor - An unnamed investor

2026Q2: After completing Cohort 8 and obtaining the 12-week data, Sarepta will approach the FDA to discuss the regulatory path. The exact nature of the path (e.g., label expansion) will be defined at that time. - [Michael Severino](CEO)

Is the ALI data from the FDA sufficient to make a decision on Cohort 8, potentially leading to reinstating the indication, and could you discuss the eight-month SNDA review timeline for Vyondys and Amondys and its implications? - David Hoang (Deutsche Bank)

2026Q1: The company will meet with the FDA upon data availability to discuss the path forward. The goal is to have a thoughtful conversation with physicians and families to potentially offer ELEVIDYS to non-ambulatory patients, given the urgent need. - [Dr. Louise Rodino-Klapac](President of R&D) and [Doug Ingram](CFO)

Contradiction Point 5

Cohort 8 Data Timeline (vs. 2025 Q4)

Contradictory statements on when the primary Cohort 8 data will be available.

An unnamed investor - An unnamed investor

2026Q2: Regarding Cohort 8 data, the primary goal is to assess the impact on acute liver injury (ALI). Biopsy data... is being collected, but the timing of its release was not specified. - [Michael Severino](CEO), [Patrick Moss](CCO), [Louise Rodino-Claypack](President of R&D)

What is the time lag to revenues for Elevitus, and will cohort eight in Q1 next year include expression data beyond liver safety in the top-line release? - Joshua Fleishman (TD Cowen)

20260226-2025 Q4: The trial is on track to present findings by the end of 2026. - [Louise Rodino-Klapac](Chief Medical Officer)